Degenerative Arthritis
Conditions
Brief summary
The purpose of this study is to investigate the efficacy and safety of autologous transplantation of Adipose Tissue derived Mesenchymal stem cells (MSCs) in patient with degenerative arthritis.
Detailed description
degenerative arthritis is the most common type of arthritis. It is estimated that 26.9 million Americans 25 years old or older have clinical degenerative arthritis of some joints, with a higher percentage of affliction in the older population. Its clinical manifestations include joint pain and impairment to movement, and surrounding tissues are often affected with local inflammation. The etiology of degenerative arthritis is not completely understood; however, injury, age, and genetics have been considered among the risk factors. Degenerative arthritis is a progressively debilitating disease that affects mostly cartilage, with associated changes in bone. Cartilage has limited intrinsic healing and regenerative capacities. Due to the increasing incidence of degenerative arthritis and the aging population coupled with inefficient therapeutic choices, novel cartilage repair strategies are in need. The availability of large quantities of MSCs and their potential for ready chondrogenic differentiation after prolonged in vitro expansion have made MSCs the most hopeful candidate progenitor cell source for cartilage tissue engineering. In the clinical study, mesenchymal stem cells will be isolated from adipose tissue and cultured, and administered into the cartilage tissue lesion by orthopedic surgery. It will be stimulate the regeneration of defective cartilage tissue and to improve their functions.
Interventions
Intra-articular infusion of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 1x10e7 cells/3mL,5x10e7 cells/3mL, 1x10e8 cells/3mL
Sponsors
R-Bio
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Subjects who understand and sign the consent form for this study. * Age :18-75, males and females. * Clinical diagnosis of degenerative arthritis by Radiographic Criteria of Kellgren and Lawrence. * Patients who can't treat with traditional medication and need a arthroplasty. * Patients whose lesion is 2\ 6 cm2 in size. * Duration of pain over Grade 4(11-point numeric scale) : \> 4 months
Exclusion criteria
* Women who are pregnant or breast feeding or planning to become pregnant during the study. * Objects who administer with a anti-inflammatory drugs contain herbal medicine within 14 days prior to inclusion in the study. * History or current evidence of alcohol or drug abuse or is a recreational user of illicit drugs or prescription medications. * Treatment with intra-articular injection therapy within 2 months prior to screen. * Other joint diseases except degenerative arthritis : systemic or rheumatic or inflammatory chondropathy, chondrocalcinosis, hemachromatosis, inflammatory joint disease, avascular necrosis of the femoral head, Paget's disease, hemophilic arthropathy, infectional arthritis, Charcot's disease, villonodular synovitis, synovial chondromatosis. * Positive serology for HIV-1 orHIV-2, Hepatitis B (HBsAg, Anti-HCV-Ab), Hepatitis C (Anti-HCV-Ab) and syphilis. * Serious pre-existing medical conditions like Cardiovascular Diseases, Renal Diseases, Liver Diseases, Endocrine Diseases, Cancer and Diabetes Mellitus. * Overweight expressed as body mass index (BMI) greater than 30 (obesity grade II). BMI estimated as mass (kg) / corporal surface (m2). * Participation in another clinical trial or treatment with a different investigational product within 3 months prior to inclusion in the study. * Other pathologic conditions or circumstances that difficult participation in the study according to medical criteria.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety evaluation | 24 weeks | To determine the overall safety of RNL-JointStem® carrier using physical examinations, vital signs, treatment emergent adverse events (TEAEs), and the results of clinical lab tests. |
| WOMAC(Western Ontario and McMaster Universities) Index | 24 weeks | Pain as measured by the The Western Ontario and McMaster Universities Arthritis Index (WOMAC) Pain Score. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| KSCRS(Knee Society Clinical rating System) | 24 weeks | Changes in exercise score and function of joint evaluation by KSCRS(Knee Society Clinical rating System). |
| Magnetic Resonance Imaging | 24 weeks | Changes in the MRI knee with cartilage mapping and clinical improvement assessed by radiologist. |
| VAS(11-point box visual analogue scale) | 24 weeks | Changes in VAS(11-point box visual analogue scale) score. |
| Histological evaluates | 24 weeks | Biopsy specimens subject to safranin-O staining and immunohistochemistry for type I and II collagen. Thickness of the articular cartilage before and after injection measure, and specimens evaluate with ICRS II by a blind histopathologist. |
Other
| Measure | Time frame | Description |
|---|---|---|
| X-ray | 24 weeks | X-ray perform to measure with Kellgren-Lawrence grade,20 joint space width of the medial compartment,21 mechanical axis with weight bearing line,22 and anatomical axis. |
| Arthroscopy | 24 weeks | Arthroscopy performs to evaluate any change in cartilage defect at the time of cell injection, and at 6 months after injection |
| cartilage volume of the knee joint | 24 weeks | changes of the cartilage volume of the knee joint measure using a semi-automated segmentation method by a blinded researcher (webappendix) |
Countries
South Korea
Outcome results
None listed